Integrated Multi-Omics and Network Pharmacology Reveal the Targeted Alleviation of MASLD by Litchi Pericarp Oligomeric Polyphenols via Quercetin.
- 1Lab of Applied Biocatalysis, School of Food Science and Engineering, South China University of Technology, No. 381 Wushan Road, Guangzhou 510640, China.
- 2Sericultural & Agri-Food Research Institute, Guangdong Academy of Agricultural Sciences, No. 133 Yiheng Street, Dongguanzhuang Road, Tianhe District, Guangzhou 510610, China.
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) represents a major global metabolic health burden, driving an urgent demand for safe, natural bioactive therapeutics derived from sustainable botanical sources. This study aimed to investigate the therapeutic efficacy and multi-target molecular mechanisms of litchi pericarp oligomeric polyphenols (LPPO) from Litchi chinensis Sonn. cv. Feizixiao against MASLD. A comprehensive multi-tiered pharmacological study design was conducted, integrating computational target prediction (network pharmacology and molecular docking) with in vitro cellular and in vivo animal disease models, combined with multi-omics profiling. Palmitate/oleate (FFA)-induced HepG2 cells and high-fat-diet (HFD)-fed C57BL/6J mice (JAX substrain) were treated with LPPO to evaluate hepatic steatosis, serum lipid profiles, oxidative stress parameters, and fecal lipid excretion. Integrated transcriptomics, metabolomics, network pharmacology, and molecular docking were conducted to pinpoint core bioactive constituents and validate key molecular targets and signaling pathways. LPPO markedly attenuated hepatic lipid accumulation, normalized serum lipid levels (TC, TG, and LDL-C), restored cellular redox balance (SOD and MDA), and promoted systemic lipid clearance via enhanced fecal excretion both in vitro and in vivo. Multi-omics integration identified quercetin as the principal bioactive metabolite driving LPPO-mediated metabolic reprogramming. Mechanistically, LPPO directly bound ALOX5 and downregulated ALOX12B to inhibit arachidonic acid-mediated inflammatory cascades, while suppressing NOS2/DUOX1 and upregulating MPV17L2 to alleviate oxidative/nitrosative stress. Additionally, quercetin downregulated the CD274 (PD-L1) checkpoint axis to reverse hepatic immunosuppression, alongside modulating GMPR, BCKDHA, and IDI1 to rebalance cellular energy allocation and lipid remodeling. LPPO exerts potent multi-target therapeutic effects against MASLD by alleviating lipotoxicity, oxidative stress, and inflammatory cascades. These findings elucidate the molecular basis of LPPO and highlight the potential of litchi pericarp waste as a high-value phytomedicinal resource.
Related
- Quercetin and tumor microenvironment associated pathways in lung cancer: a network pharmacology and in vitro study
- Quercetin attenuates acute inflammation and extracellular matrix remodeling after intracerebral hemorrhage: transcriptomics-informed network pharmacology and experimental validation
- Exploring the association of quercetin with liver fibrosis through network pharmacology and 16S rRNA gene sequencing
- Integrated Chemical Profiling and Toxicological Assessment of Total Polyphenols from Cydonia oblonga Mill. Reveals Potential Safety Concerns Under High-Dose Exposure.
- Integrated network pharmacology, in vivo experiment, computational biology, and metabolomics to explore the mechanism of astragaloside IV against spinal cord injury
BibTeX
@article{xiao2026integrated,
title = {{Integrated Multi-Omics and Network Pharmacology Reveal the Targeted Alleviation of MASLD by Litchi Pericarp Oligomeric Polyphenols via Quercetin.}},
author = {Lu Xiao and Jin-Wen Tang and Ya Mao and Yuan-Shan Yu and Xin Li and Wen-Yong Lou},
journal = {Antioxidants (Basel, Switzerland)},
year = {2026},
month = sep,
doi = {10.3390/antiox15101246},
url = {https://europepmc.org/article/MED/42939820},
note = {CC BY},
}
RIS
TY - JOUR
TI - Integrated Multi-Omics and Network Pharmacology Reveal the Targeted Alleviation of MASLD by Litchi Pericarp Oligomeric Polyphenols via Quercetin.
AU - Lu Xiao
AU - Jin-Wen Tang
AU - Ya Mao
AU - Yuan-Shan Yu
AU - Xin Li
AU - Wen-Yong Lou
PY - 2026
DA - 2026/09/27
JO - Antioxidants (Basel, Switzerland)
DO - 10.3390/antiox15101246
UR - https://europepmc.org/article/MED/42939820
AB - Metabolic dysfunction-associated steatotic liver disease (MASLD) represents a major global metabolic health burden, driving an urgent demand for safe, natural bioactive therapeutics derived from sustainable botanical sources. This study aimed to investigate the therapeutic efficacy and multi-target molecular mechanisms of litchi pericarp oligomeric polyphenols (LPPO) from Litchi chinensis Sonn. cv. Feizixiao against MASLD. A comprehensive multi-tiered pharmacological study design was conducted, integrating computational target prediction (network pharmacology and molecular docking) with in vitro cellular and in vivo animal disease models, combined with multi-omics profiling. Palmitate/oleate (FFA)-induced HepG2 cells and high-fat-diet (HFD)-fed C57BL/6J mice (JAX substrain) were treated with LPPO to evaluate hepatic steatosis, serum lipid profiles, oxidative stress parameters, and fecal lipid excretion. Integrated transcriptomics, metabolomics, network pharmacology, and molecular docking were conducted to pinpoint core bioactive constituents and validate key molecular targets and signaling pathways. LPPO markedly attenuated hepatic lipid accumulation, normalized serum lipid levels (TC, TG, and LDL-C), restored cellular redox balance (SOD and MDA), and promoted systemic lipid clearance via enhanced fecal excretion both in vitro and in vivo. Multi-omics integration identified quercetin as the principal bioactive metabolite driving LPPO-mediated metabolic reprogramming. Mechanistically, LPPO directly bound ALOX5 and downregulated ALOX12B to inhibit arachidonic acid-mediated inflammatory cascades, while suppressing NOS2/DUOX1 and upregulating MPV17L2 to alleviate oxidative/nitrosative stress. Additionally, quercetin downregulated the CD274 (PD-L1) checkpoint axis to reverse hepatic immunosuppression, alongside modulating GMPR, BCKDHA, and IDI1 to rebalance cellular energy allocation and lipid remodeling. LPPO exerts potent multi-target therapeutic effects against MASLD by alleviating lipotoxicity, oxidative stress, and inflammatory cascades. These findings elucidate the molecular basis of LPPO and highlight the potential of litchi pericarp waste as a high-value phytomedicinal resource.
SN - 2076-3921
ER -